Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct 1;3(10):1289-1292.
doi: 10.1002/hep4.1420. eCollection 2019 Oct.

Fine-Tuning TLR-7-Based Therapy for Functional HBV Cure

Antonio Bertoletti  1   2 , Nina Le Bert  1
Affiliations
Editorial

Fine-Tuning TLR-7-Based Therapy for Functional HBV Cure

Antonio Bertoletti et al. Hepatol Commun. .

Abstract

This is an invited editorial on the editorial on the original manuscript HEP4-19-0099.R1" "Liver-targeted TLR7 agonist combined with Entecavir promotes a functional cure in the woodchuck model of chronic HBV."

PubMed Disclaimer

Figures

Figure 1
Figure 1
TLR‐7 agonist's immunological mechanisms. TLR‐7 agonist (as APR002) acts by targeting intrahepatic plasmacytoid dendritic cells (PDCs) and B cells. TLR‐7 agonist triggers type I IFN production in PDC. Type I IFNs have a direct antiviral effect on HBV‐infected hepatocytes but also activate intrahepatic NK or T cells. TLR‐7 agonist on B cells can induce their functional maturation to plasma cells (both in the liver and peripheral blood).
See this image and copyright information in PMC

References

    1. Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol 2016;64:S60‐S70. - PubMed
    1. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, et al. GS‐9620, an oral agonist of toll‐like receptor‐7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013;144:1508‐1517. - PMC - PubMed
    1. Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH, et al. Sustained efficacy and seroconversion with the toll‐like receptor 7 agonist GS‐9620 in the woodchuck model of chronic hepatitis B. J Hepatol 2015;62:1237‐1245. - PMC - PubMed
    1. Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen A‐H, et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS‐9620) in virally suppressed patients with chronic hepatitis B. J Hepatol 2018;68:431‐440. - PubMed
    1. Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, et al. TLR7 agonist increases responses of hepatitis B virus‐specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Gastroenterology 2018;154:1764‐1777. - PubMed

Publication types